The in vitro and in vivo experiments suggested that miR-552-3p inhibited multiple fibrotic and inflammatory genes, and down-regulated the TGF-β1/Smad3 signaling pathway via inhibiting SMAD3 and TGFBR2, thus ameliorating liver fibrosis and inflammation. Here, SMAD3 is linked to Hepatic fibrosis.